TOP HEADLINES

Featured Story

  • NIH turns on Big Data funding faucet

    The National Institutes of Health (NIH) has kicked off its Big Data to Knowledge (BD2K) initiative with an initial $32 million in funding. Harvard, Stanford and other universities received some of the cash to set up Centers of Excellence for Big Data Computing, each of which will tackle a different aspect of turning numbers into biomedical understanding. Read more >>

EMA to discuss possible glitch in Thermo bioequivalence software

Increased reliance on software to support aspects of drug development has simplified many tasks but created the possibility that an IT glitch could have far-reaching implications. Now, the European Medicines Agency is to discuss whether this situation has already happened.

Regeneron allies with DNAnexus on 100,000 exomes project

Faced with the challenge of how to handle data from the 100,000 exomes it intends to sequence, Regeneron has struck a deal with DNAnexus to access cloud-based infrastructure.The biotech is working with DNAnexus through the Regeneron Genetics Center it established for the sequencing project.

Genomics England picks 10 firms for next round of bioinformatics talent contest

Genomics England has dropped two-thirds of the candidates to provide variant annotation and clinical interpretation services to the 100,000 Genomes Project after reviewing the first round of responses.

Researchers join forces to build database of 50M genetic variants

The genetic research community is about to get access to a lot of data. On October 20, two public databases generated by whole-genome and exome sequencing at multiple research institutions will be unveiled.

BBK inks deal to buy mobile app development unit

The acquisition tightens BBK's ties to the team that helped to develop its patient and site engagement mobile app, My Clinical Study Buddy.

MORE NEWS

From Our Sister Sites

FierceVaccines

To help show Americans just how important its flu vaccines are, Novartis has teamed up with entertainer Nick Cannon, who's advising consumers to prepare for flu season by getting their shots and stocking up on the Swiss pharma's over-the-counter remedy, Theraflu.

FierceVaccines

GlaxoSmithKline's vaccines unit will be getting a new look come next year, when it's expected to absorb the bulk of Novartis' vaccines lineup it bought for $7.1 billion back in April. It'll have some new management, too, with Moncef Slaoui in the chairman's role. And judging from the pharma giant's Q3 results, some change for the unit could be a good thing.